Ofatumumab Based Chemoimmunotherapy (CIT) for Patients with Previously Untreated CLL

被引：0
|
作者：
Shanafelt, Tait D. [1 ]
Lanasa, Mark C. [2 ]
Zent, Clive S. [1 ]
Leis, Jose F. [3 ]
Call, Timothy G. [1 ]
LaPlant, Betsy R.
Tun, Han [4 ]
Bowen, Deborah A. [1 ]
Jelinek, Diane F. [5 ]
Hanson, Curtis A. [6 ]
Kay, Neil [1 ]
机构：
[1] Mayo Clin, Div Hematol, Rochester, MN USA
[2] Duke Univ, Med Ctr, Durham, NC USA
[3] Mayo Clin Arizona, Div Hematol & Med Oncol, Scottsdale, AZ USA
[4] Mayo Clin Jacksonville, Jacksonville, FL 32224 USA
[5] Mayo Clin, Dept Immunol, Rochester, MN USA
[6] Mayo Clin, Div Hematopathol, Dept Lab Med, Rochester, MN USA
来源：
BLOOD | 2011年 / 118卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1665 / 1666
页数：2
相关论文
共 50 条
  • [11] Lenalidomide Consolidation Appears to Prolong Time to Retreatment After First-Line Chemoimmunotherapy for Patients with Previously Untreated CLL
    Shanafelt, Tait D.
    Tun, Han
    Hanson, Curtis A.
    Zent, Clive S.
    Leis, Jose F.
    Call, Timothy G.
    LaPlant, Betsy R.
    Bowen, Deborah
    Pavey, EmilyS S.
    Jelinek, Diane F.
    Kay, Neil
    BLOOD, 2011, 118 (21) : 1666 - 1667
  • [12] a Phase 2 Study of Alemtuzumab-Ofatumumab (A plus O) Combination in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL)
    Ma, Shuo
    Rosen, Steven T.
    Frankfurt, Olga
    Winter, Jane N.
    Kreutzer, Jennifer
    Husa, Sonja
    Otsterborg, Anders
    Lundin, Jeanette
    BLOOD, 2014, 124 (21)
  • [13] Cost-Effectiveness Analysis of Obinutuzumab Versus Ofatumumab for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
    Reyes, Carolina
    Gazauskas, Gregory
    Becker, Ursula
    Moreno, Santiago
    Veenstra, David L.
    BLOOD, 2014, 124 (21)
  • [14] Ofatumumab combined with CHOP in previously untreated patients with follicular lymphoma (FL)
    Czuczman, M. S.
    Viardot, A.
    Hess, G.
    Gadeberg, O. V.
    Pedersen, L. M.
    Gupta, I.
    Lin, T. S.
    Strange, C.
    Windfeld, K.
    Russell, C. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [15] Ibrutinib followed by ofatumumab consolidation in previously untreated patients with chronic lymphocytic leukemia (CLL): GELLC-7 trial from the Spanish group of CLL (GELLC)
    Abrisqueta, Pau
    Gonzalez-Barca, Eva
    Ferra, Christelle
    Rios-Herranz, Eduardo
    de la Mata, Margarita Fernandez
    Delgado, Julio
    Andreu, Rafael
    Hernandez-Rivas, Jose angel
    Terol, Maria Jose
    Navarro, Almudena
    Vidriales, M. Belen
    Baltasar, Patricia
    De la Serna, Javier
    Ramirez, Angel
    Ballester, Carmen
    Moreno, Carol
    Garcia-Marco, Jose Antonio
    Cordoba, Raul
    Yanez, Lucrecia
    Casado, Luis Felipe
    Gonzalez, Marcos
    Bosch, Francesc
    ECLINICALMEDICINE, 2024, 73
  • [16] Risk-Adapted Induction and Maintenance with Ofatumumab in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)
    Ahn, Inhye
    Farooqui, Mohammed
    Lee, Yuh Shan
    Marti, Gerald
    Soto, Susan
    Tian, Xin
    Stetler-Stevenson, Maryalice
    Yuan, Constance M.
    Maric, Irina
    Wiestner, Adrian
    BLOOD, 2015, 126 (23)
  • [17] A Phase 2 Study of Alemtuzumab-Ofatumumab (A plus O) Combination in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) - an Update
    Lundin, Jeanette
    Rosen, Steven T.
    Osterborg, Anders
    Frankfurt, Olga
    Winter, Jane N.
    Rademaker, Alfred
    Kreutzer, Jennifer
    Bacon, Elizabeth
    Sonnert-Husa, Sonja
    Ma, Shuo
    BLOOD, 2015, 126 (23)
  • [18] Combination therapies for previously untreated CLL
    Shanafelt, Tait D.
    Kay, Neil E.
    LANCET, 2007, 370 (9583): : 197 - 198
  • [19] Correlations Between Ofatumumab Exposure and Treatment Outcomes for patients with Chronic Lymphocytic Leukemia (CLL) Treated with Frontline Ofatumumab, Fludarabine, and Cyclophosphamide Chemoimmunotherapy
    Wierda, William G.
    Jewell, Roxanne C.
    Kipps, Thomas J.
    Duerig, Jan
    Griskevicius, Laimonas
    Stilgenbauer, Stephan
    Smolej, Lukas
    Hess, Georg
    Hernandez-Ilizaliturri, Francisco J.
    Padmanabhan, Swaminathan
    Fang, Lei
    Gorczyca, Michele M.
    Chan, Geoffrey W.
    Gupta, Ira V.
    Lisby, Steen
    BLOOD, 2011, 118 (21) : 782 - 783
  • [20] Preliminary Results of Ibrutinib Followed By Ofatumumab Consolidation in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL): GELLC7 Trials from the Spanish Group of CLL (GELLC)
    Abrisqueta, Pau
    Gonzalez-Barca, Eva
    Ferra, Christelle M.
    Rios Herranz, Eduardo
    Fernandez, Margarita
    Delgado, Julio
    Andreu, Rafael
    Angel Hernandez-Rivas, Jose
    Jose Terol, Maria
    Gonzalez, Marcos
    Baltasar Tello, Patricia
    de la Serna, Javier
    Ramirez Payer, Angel
    Ballester, Carmen
    Moreno, Carol
    Garcia-Marco, Jose A.
    Cordoba, Raul
    Yanez San Segundo, Lucrecia
    Casado Montero, Luis Felipe
    Bosch, Francesc
    BLOOD, 2019, 134
12345